Continuous Flow Manufacture of Active Pharmaceutical Ingredients -

Continuous Flow Manufacture of Active Pharmaceutical Ingredients

How Equilibar Back Pressure Valves are Used in Continuous Flow API

  • Active Pharmaceutical Ingredient (API) process control schematic
Active Pharmaceutical Ingredients or APIs are manufactured through chemical and physical processes, which can be a complex multi-step process using a range of technologies. An Active Pharmaceutical Ingredient is defined as the substance used in a pharmaceutical product that delivers the pharmacological activity designed to cure, mitigate, treat or prevent disease. APIs are commonly referred to as Bulk Pharmaceuticals.

Why a back pressure regulator is useful in continuous flow control

The effectiveness of a continuous flow process is determined by the precision and consistency of the flow measurement and control equipment. Therefore, it is critical to choose the appropriate control valve for the application. Many flow control schemes use variable orifice control valves in conjunction with flow transmitters and a closed-loop PID controller. An alternative method of flow control is to employ a dome-loaded back pressure regulator (BPR) to control flow by controlling the pressure drop across an orifice. By using a BPR, the flow control will be buffered from downstream changes in flow and pressure, creating a more consistent continuous flow process.

Equilibar has unique dome-loaded, multiple-orifice control valve technology that offers superior precision and frictionless control, especially for low flow rates, mixed phase fluids, corrosive media, and extreme temperatures.

Active Pharmaceutical Ingredient (API) process control schematic

In the schematic above, two reactants are pumped continuously into a heated API reactor. Here the Equilibar® back pressure regulator provides a stable flow through the reactor that ensures a steady residence time and reaction speed, resulting in the desired full reactant conversion and consistent final product.

The ability of the Equilibar BPR to control the process at high temperature and high pressure increases effective residence time and reaction rate. Precise pressure control keeps the reaction at the desired phase throughout the process. Together these qualities deliver higher product yield and consistency, resulting in lower cost and better quality.

Certification Considerations in API Manufacturing

API manufacturers must adhere to strict safety and quality standards set by the country where it will be sold. Manufacture of products used in the US will be overseen by the FDA. If the API will be used in Europe, manufacturers must meet regulations of the European Medicines Agency.

Many API’s are manufactured using catalyzed reactors that require stable pressure control at elevated temperatures. Some formulations require highly corrosion resistant metals such as Hastelloy C276 and elastomers such as Kalrez FFKM. Equilibar’s simple design consists of one moving diaphragm and an optional wetted O-ring. This allows Equilibar to adapt standard designs to meet demanding requirements of pharma. Equilibar diaphragms can be made of FDA and European Medicines Agency approved materials.

Certifications for Equilibar back pressure regulators are available upon request to conform to the requirements certifying agencies.

Contact an application engineer for more information about using an Equilibar back pressure regulator in your continuous flow chemistry or API process.

Equilibar GS valve with QPV electronic controller

Equilibar GSD4 1/2″ stainless steel BPR with electronic pilot regulator may be a good option for API process control

 


 

Learn more about our back pressure regulator technology and how it works.

Watch this video how the Equilibar Back Pressure Regulator works.

Work Categories
Equilibar News
Photo of Biopharma product managers Steriflow and Equilibar

Q&A on single-use and multi-use fluid control for biopharma processes

From single-use valves for TFF to a redesigned sanitary safety relief valve, Equilibar and Steriflow have been exploring synergistic ways to combine two distinct technologies to create better fluid control solutions for the biopharmaceutical industry since 2021. As they prepare for the April 2024 INTERPHEX show in New York City, Single Use Technology Manager Ryan Read More

Read More